The salvage lenvatinib-based regimen provides survival benefit in patients with refractory metastatic colorectal cancer.
Kao YC, Yang MY, Chen WS, Jiang JK, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Lin YZ, Yang YW, Teng HW.
Kao YC, et al. Among authors: yang my.
Am J Cancer Res. 2024 May 15;14(5):2187-2201. doi: 10.62347/YKZB8359. eCollection 2024.
Am J Cancer Res. 2024.
PMID: 38859851
Free PMC article.